Artelus.ai Company Profile

Background

Artelus.ai, short for Artificial Learning Systems, is a pioneering healthcare technology company specializing in artificial intelligence (AI)-driven diagnostic solutions. Founded in 2017, the company's mission is to leverage deep learning technology to democratize healthcare access, particularly for underserved populations, referred to as the "Forgotten Billions." Artelus focuses on developing advanced screening tools for the early detection of diabetic retinopathy and other retinal pathologies, aiming to prevent avoidable blindness and improve global health outcomes.

Key Strategic Focus

Artelus's strategic objectives center on:

• Early Detection of Retinal Diseases: Utilizing AI to identify conditions like diabetic retinopathy at initial stages, facilitating timely intervention.

• AI-Driven Diagnostic Tools: Developing proprietary deep learning algorithms to enhance diagnostic accuracy and efficiency.

• Global Healthcare Impact: Expanding the reach of their solutions to underserved regions, ensuring equitable access to quality eye care.

Financials and Funding

While specific funding details are not publicly disclosed, Artelus has achieved significant milestones, including:

• Awards and Recognitions:

• Winner of the NASSCOM EMERGE50 League-of-Ten (November 2023).

• Winner of the LVPEI Eye Care Start-up Competition (April 2023).

• Winner of the Qualcomm Design in India Challenge (March 2019).

• Winner at the Technology Innovation Pioneers (Healthcare) challenge (February 2019).

• Winner at the Digital Innovation Challenge (February 2019).

• Runner-up at Pitch@Palace (October 2018).

• Finalist at The Start Tel Aviv (July 2017).

• Patents: Filed 13 patents, with 8 approved, showcasing innovation in AI-driven healthcare solutions.

Pipeline Development

Artelus has developed several key products:

• Sushruta: An early identification screening tool for diabetic retinopathy.

• Hansanet: Grades the quality of retina images captured during screenings.

• Nimi: Segments abnormalities in fundus images, aiding accurate diagnosis.

• AI-Powered COVID-19 Screening Software: Identifies COVID-19, pneumonia, and tuberculosis from chest X-rays with accuracy comparable to radiologists.

Future projects include validation and data gathering for tuberculosis, lung cancer, breast cancer, and multiple sclerosis.

Technological Platform and Innovation

Artelus's technological innovations include:

• Proprietary Deep Learning Algorithms: Modeled on neural networks, these algorithms improve diagnostic accuracy and speed with each scan.

• Generative Adversarial Networks (GANs): Used to generate synthetic medical images, augmenting datasets and enhancing AI model training.

• Explainable AI: Provides heatmaps highlighting regions of interest, ensuring transparency and aiding clinical decisions.

Leadership Team

• Pradeep Walia: Founder of Artelus.ai, leading the company's vision and strategic direction.

• Anjo De Heus: Appointed as Chief Commercial Officer in June 2024, bringing extensive experience in commercial strategy to drive growth and market expansion.

Leadership Changes

In June 2024, Anjo De Heus joined Artelus.ai as Chief Commercial Officer, aiming to enhance the company's market presence and accelerate its mission to revolutionize healthcare with AI technology.

Competitor Profile

Market Insights and Dynamics

The AI-driven healthcare diagnostics market is experiencing rapid growth, driven by the increasing prevalence of chronic diseases and the need for efficient diagnostic solutions. The integration of AI in healthcare is projected to be a multi-billion-dollar industry, significantly impacting disease detection and management.

Competitor Analysis

Key competitors in the AI-driven retinal diagnostics space include:

• IDx Technologies: Focuses on autonomous AI systems for the detection of diabetic retinopathy.

• Eyenuk: Develops AI solutions for eye disease screening and monitoring.

• Retina-AI Health: Specializes in AI-based diagnostic tools for retinal diseases.

These companies emphasize AI-driven diagnostic accuracy, regulatory approvals, and integration with existing healthcare workflows.

Strategic Collaborations and Partnerships

Artelus has engaged in collaborations to strengthen its market position and innovation capacity:

• Dubai Health Authority: Positive feedback for integrating Artelus's technology into healthcare systems.

• LV Prasad Eye Institute (LVPEI): Winner of the LVPEI Eye Care Start-up Competition, indicating collaboration in advancing eye care solutions.

Operational Insights

Artelus differentiates itself through:

• Comprehensive AI Solutions: Offering a suite of diagnostic tools addressing multiple retinal conditions.

• Global Reach: Operations across 286 locations, including offices in the USA, Bangalore, Kolkata, and Mumbai, with distributors in the UK, UAE, Australia, and South Africa.

• Focus on Underserved Populations: Commitment to bringing healthcare to the "Forgotten Billions" by making diagnostics accessible and affordable.

Strategic Opportunities and Future Directions

Artelus aims to:

• Expand Product Portfolio: Develop screening tools for additional diseases like tuberculosis, lung cancer, and breast cancer.

• Enhance AI Capabilities: Continuously improve AI algorithms for higher accuracy and efficiency.

• Strengthen Global Partnerships: Collaborate with healthcare organizations to broaden the adoption of AI-driven diagnostics.

Contact Information

Artelus.ai continues to innovate in AI-driven healthcare solutions, striving to make quality diagnostics accessible to all, especially underserved populations.